Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reiterated by analysts at Goldman Sachs Group in a note issued to investors on Tuesday. They presently have a $45.00 price target on the biopharmaceutical company’s stock. Goldman Sachs Group’s price objective suggests a potential upside of 8.43% from the stock’s previous close.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. reaffirmed a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Morgan Stanley reaffirmed a “buy” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, June 11th. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, June 13th. Morningstar set a $43.50 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Tuesday, July 3rd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company. Pfizer currently has an average rating of “Hold” and an average target price of $41.74.

PFE opened at $41.50 on Tuesday. The stock has a market capitalization of $252.40 billion, a PE ratio of 15.66, a P/E/G ratio of 2.05 and a beta of 0.96. Pfizer has a 1-year low of $33.20 and a 1-year high of $42.77. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 EPS. equities analysts expect that Pfizer will post 2.99 EPS for the current year.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 25,642 shares of the business’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $39.51, for a total transaction of $1,013,115.42. Following the transaction, the insider now directly owns 127,954 shares of the company’s stock, valued at $5,055,462.54. The disclosure for this sale can be found here. Insiders have sold a total of 785,453 shares of company stock valued at $29,937,357 over the last three months. 0.06% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Ballew Advisors Inc acquired a new stake in shares of Pfizer in the 1st quarter worth approximately $102,000. Earnest Partners LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $105,000. First Dallas Securities Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $118,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $118,000. Finally, Fort L.P. acquired a new stake in shares of Pfizer in the 2nd quarter worth approximately $121,000. 69.12% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: What does EPS mean?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.